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CONCLUSION: Average medical costs of treatment
were the highest for patients with no recorded comorbid-
ity in 1995. In contrast, the median cost estimates were
the lowest for these patients. Results indicated that distri-
butions of medical costs were positively skewed; the ob-
servation was most prominent in the population with no
recorded comorbidities associated with type-2 diabetes
mellitus. This finding may result from several factors in-
cluding coding, severity, and/or compliance.
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Diabetes is a chronic illness with type 2 diabetes repre-
senting 80% of all diagnosed diabetes. In recent years, a
number of instruments have been developed to measure
the HRQOL of patients with type 2 diabetes. Good psy-
chometric properties of these instruments are important
for their use in studies evaluating the effect of interven-
tions to increase metabolic control. OBJECTIVE: To re-
view the QOL literature with focus on HRQOL measure-
ments in type 2 diabetes. METHOD: We identified HRQOL
instruments for type 2 diabetes using MEDLINE (En-
glish), and reviewed the resulting publications for evi-
dence of reliability, validity, and responsiveness. RE-
SULTS: Several English-language generic and disease-
specific measures were identified. These instruments have
been used both in mixed diabetes populations and in
solely type 2 patients, including insulin users. The instru-
ments in the studies reviewed have acceptable reliability
and validity in tested populations. Few of these HRQOL
measures have been tested for sensitivity to changes in
metabolic control through pharmacological or non-phar-
macological interventions. One recently published drug
study provided support for the responsiveness of scales in
an unpublished HRQOL instrument. CONCLUSIONS:
Generic instruments such as the MOS SF-36 and EQ5D
may or may not be sensitive to change in HRQOL related
to diabetes and its treatment. Disease-specific instru-
ments have shown more sensitivity, but may fail to cap-
ture all relevant domains and do not apply to the specific
diabetes population under investigation. The responsive-
ness of instruments has not been addressed adequately in
the studies. More studies are needed to further assess reli-






Average Median Average Median
Nhtn 1,964 471 427 184
Nhlpd 1,197 571 374 225
Nnoco 2,735 456 594 166
ability, validity and most importantly, responsiveness of
the existing instruments.
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OBJECTIVE: To develop a method to test the hypothesis
that DM and HT are the most frequent concomitant ill-
nesses among such disease groups as cardiovascular
(CVD), joint disorders, renal failure, liver and kidney dis-
eases and to calculate the annual medical care costs of
HT and DM compared with estimated average care costs
in the disease groups. METHODS: Diagnosis-specific es-
timates for health care utilization and associated medical
expenses were constructed by employing a linear model
with exogenous population weights and normalizing co-
efficients using the National Medical Expenditure Survey
data. Statistical analyses for demographic parameters and
design effects on mean cost were obtained using linear re-
gression models. RESULTS: Among diabetics the most
prevalent conditions were HT (40%), CVD (26%), joint
disorders (23%), and fatigue (21%). DM and any of the
15 comorbidities incurred annual average costs ranging
from $2000 to $48,100, 1.5 to 3.5-fold higher than the
estimated disease-specific average costs. Among patients
with HT the most prevalent conditions were joint disor-
ders (23%), CVD (22%), fatigue (20%), and DM (18%).
HT and any of the 15 comorbidities incurred annual av-
erage medical costs 1.3–2.5-fold higher than the esti-
mated disease-specific average medical costs. Patients
with DM and HT constitute over 60% of all patients
treated annually for CVD, 52% for renal failure, 55%
for joint disorders and 45% with liver diseases. Federal
programs compensate 38% of medical care costs in HT
and 56% in DM. Out-of-pocket expenses pay 37% of
costs in HT and 20% in DM. CONCLUSION: Our find-
ings suggest that HT and DM are responsible for more
than 60% of health care costs in some of the 15 re-
searched disease categories. Treating of DM and HT to
goal will help to contain medical care costs for health
care providers and payers irrespective of any other co-
morbidity, and contribute to cost-effective disease man-
agement, and quality of care.
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In the past decade, the HMG CoA reductase inhibitors
(HMGs) have revolutionized the treatment of hyperlipi-
demia. OBJECTIVES: The primary objective of this
study was to determine the relationship between the use
of HMGs and cardiovascular events in a diabetic hyper-
tensive population from a managed care perspective. The
secondary objective was to estimate any differences in
overall health care costs (e.g. hospitalizations, emergency
room visits, and pharmacy cost) between patients taking
HMGs and those who are not. METHODS: Retrospec-
tive computerized claims from a managed care organiza-
tion were analyzed (N  6739). Patients were included if
they had an ICD-9 diagnosis code for diabetes mellitus
and hypertension between 9/1/95 and 8/31/96. During
the identification period, patients who received an HMG
were included in the HMG group. Patients who never re-
ceived an HMG were included in the control group. All
patients were followed for 3 years. RESULTS: In a multi-
variate regression analysis controlling for potential con-
founding factors such as age, gender, benefit design, dis-
ease severity, and number of comorbidities, pharmacy
cost was higher in the HMG group (Beta  $1276, P 
0.0001). Use of the HMGs were associated with fewer
emergency room visits (Beta  0.387, P  0.0001) and
fewer inpatient days (Beta  19.7, P  0.0001). Logis-
tic regression controlling for the same factors showed pa-
tients in the HMG group were less likely to experience
death compared to the control group (odds ratio, 0.435;
95% confidence interval 0.365–0.517). CONCLUSION:
The HMGs are associated with fewer emergency room
visits, hospital days, and lowers the risk of death. The
higher pharmacy costs associated with the HMGs appears
to be offset by non-pharmacy cost savings.
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OBJECTIVE: To compare the impact of a diabetes dis-
ease management program (DDMP). METHODS: A pre/
post comparison was conducted to evaluate a DDMP
program in a V.A. nursing home. All diabetic patients re-
siding as of September 1998 (pre-DDMP) were compared
with those residing there in November 1999 (post-
DDMP). Data collection included age, sex, types of diet,
functional categories, weight, body mass index (BMI),
cholesterol, hemoglobin A1C (HA1C), urinalysis, eye
and foot exams, and antidiabetic drug therapies. RE-
SULTS: The pre-DDMP group had 31 males, mean age
76 years; post-DDMP group had 36 males, mean age 77
years. Eighteen men of the 36 men were in both the pre-
and post-DDMP groups; the remaining post-DDMP
group was admitted between study periods. Post-DDMP
group had a higher average BMI (P  0.01) and func-
tional category (P  04); attributed to the men admitted
after starting the DDMP. Number of patients achieving
HA1C semi-annual testing criteria was statistically greater
in the post-DDMP sample (30 pts (83%) vs. 13 pts
(42%), P  0.001). Mean HA1C results were better in
the post-DDMP sample (6.8% vs. 8.2%, P  0.01). Post
patients were more likely to have foot exams (P 
0.001). Changes in rates for urinalysis, cholesterol, and
eye exam were not statistically significant. Twelve pre-
DDMP patients were managed by diet alone; eleven in
the post group. More post patients were managed by two
or more drugs (P  0.04) which was attributed to men
admitted after starting the DDMP. CONCLUSION:
Post-DDMP group had more HAIC testing and better av-
erage results. A major observed change was in the in-
crease usage of drug combinations which might be re-
flected in the observed improvement of glycemic control.
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OBJECTIVES: The primary objective of this study was to
analyze the Medi-Cal 5% claims database in order to es-
timate the cost of illness for overactive bladder (OAB) to
the California Medicaid program. Secondary objectives
of this study were to describe patterns of care for patients
diagnosed with overactive bladder and to discover cost
offsets that could be achieved with drug treatment of
OAB. METHODS: A continuously enrolled (1996–1997)
cohort of overactive bladder patients was identified
based upon the presence of ICD-9 diagnosis codes and
drug claims in the database. All claims (physician, hospi-
tal, long term care, drug, and medical supply) for these
patients were analyzed to determine the quantity and cost
of services provided to patients with overactive bladder.
Additional analyses were performed to determine if there
were medical costs that could be offset by drug treatment
of overactive bladder. RESULTS: Claims for OAB were
analyzed for 97,160 unique patients. The prevalence of
OAB in this continuously enrolled population was
2.95%, significantly lower that the National Survey of
OAB estimate of 22%. The average direct costs per pa-
tient were $450 per year. Ninety-six percent of these
costs were for incontinence pads and supplies. Only 13%
of patients treated with oxybutynin continued therapy
for more than 3 months. Patients treated with drug ther-
apy alone or in combination with pads cost less to treat
than patients receiving pads alone. Urologists ordered
95% of diagnostic tests. When OAB was diagnosed and
treated, the number of claims and costs for comorbid uri-
nary tract infections and skin breakdown decreased.
CONCLUSION: Patients who receive drug treatment for
